Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).

ABSTRACT:

Background

Teriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use.

Objective

To investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for key AEs, and explore potential applications to provide clinical reference.

Methods

FAERS data from 2004 to 2023 were analyzed. Reports where teriparatide was the primary suspect drug were included. Adverse events were mapped to System Organ Classes and Preferred Terms. Disproportionality analysis using ROR, PRR, BCPNN and EBGM algorithms was conducted to detect safety signals.

Results

Out of 107,123 reports with teriparatide as the primary suspect, key AEs identified included pain in extremity (PRR: 4.54), musc

SUBMITTER: Wen MT 

PROVIDER: S-EPMC11335658 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature